March 20, 2024 01:22 PM EDT

When can observational studies support a drug's effectiveness? FDA explains in new draft guidance

Zachary Brennan

Senior Editor

The FDA on Wednesday released highly-anticipated draft guidance on when drug sponsors can use observational studies to help demonstrate a drug’s effectiveness, for the first …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

When can observational studies support a drug's effectiveness? FDA explains in new draft guidance

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

FDA cancels Applied Therapeutics adcomm, shares skyrocket 65%

Here's what today's Fed rate cut means for biotech, pharma and venture capital

All of 23andMe's independent board members resign over disagreements with CEO

Roivant makes another deal, selling Dermavant to Organon for up to $1.2B

With few efficacy details, Insilico claims a Phase 2a win in latest AI readout

Breaking down silos with a new quantitative approach to drug development

When can ob­ser­va­tion­al stud­ies sup­port a drug's ef­fec­tive­ness? FDA ex­plains in new draft guid­ance

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

When can observational studies support a drug's effectiveness? FDA explains in new draft guidance